|
Emerging Cancer Vaccines: Market Forecasts, New Developments and Pipeline Analysis, 3rd Edition
|
Nov 1, 2008
250 Pages - Pub ID: KLI1646591
|
|
- TABLE OF CONTENTS
- CHAPTER ONE: EXECUTIVE SUMMARY
-
- Introduction
- Scope and Methodology
- Size and Growth of the Market
- Issues and Trends Affecting Market
- Leading Competitors
- CHAPTER TWO: INTRODUCTION
-
- Introduction
- History and Growth of the Cancer Treatment Market
- Types of Vaccines
- Antigen/Adjuvant Vaccines
- Whole Cell Tumor Vaccines
- Dendritic Cell (DC) Vaccines
- Viral Vectors and DNA Vaccines
- Idiotype Vaccines
- Types of Therapeutic Vaccines
- Patient-Specific Vaccines
- Prostate Specific Antigen
- Sialyl Tn
- Heat Shock Proteins
- Ganglioside Molecules
- Carcinoembryonic Antigen (CEA)
- MART-1
- Tyrosinase
- Adjuvants
- Industry Structure
- Demographics and Statistics
- Growing and Aging Population
- Life Expectancy and Cancer
- CHAPTER THREE: CERVICAL CANCER VACCINES
-
- Overview
- Description of Vaccines on the Market
- Gardasil/Silgard
- Cervarix
- Description of Vaccines in Development
- TG 4001/R3484
- HspE7
- Lovaxin C
- VGX-3100
- CA-9
- Market Summary
- Current and Potential Competitors and Analysis, 2012
- CHAPTER FOUR: COLON/RECTAL CANCER VACCINES
-
- Overview
- Description of Vaccines on the Market
- OncoVAX
- Description of Vaccines in Development
- OncoVAX
- TroVAX
- Avicine
- CEA VRP Vaccine
- Collidem
- IMA910
- Lapuleucel-T
- Oncophage
- CDX-1307-01
- Tumor Associated Antigen Therapeutic Vaccine - CEA DNA Cancer Vaccine
- MKC1106-PP
- Market Summary
- Potential Competitors and Analysis, 2012
- CHAPTER FIVE: LUNG CANCER VACCINES
-
- Overview
- Description of Vaccines in Development
- Lucanix
- MAGE-A3 Peptide
- Stimuvax
- EGF Cancer Vaccine
- GV-1001
- HyperAcute Lung
- IDM 2101 (EP-2101)
- Oncophage
- INGN 225
- TG 4010
- LungVAX
- Tumor Associated Antigen Therapeutic Vaccine - CEA DNA Cancer Vaccine
- DC Vax
- L523S
- Market Summary
- Potential Competitors and Analysis, 2012
- CHAPTER SIX: LYMPHOMA VACCINES
-
- Overview
- Description of Vaccines in Development
- MyVax
- BiovaxID
- FavId
- TG 1042
- Market Summary
- Potential Competitors and Analysis, 2012
- CHAPTER SEVEN: MELANOMA VACCINES
-
- Overview
- Description of Vaccines on the Market
- Description of Vaccines in Development
- M-VAX
- GMK
- Allovectin-7
- MDX-1379 with Combination Treatment MDX-010
- Oncophage
- MAGE-A3 ASCI 3
- Uvidem
- AGI-101H Vaccine
- ALVAC Vaccine
- HyperAcute Melanoma
- Market Summary
- Potential Competitors and Analysis, 2012
- CHAPTER EIGHT: PROSTATE CANCER VACCINES
-
- Overview
- Description of Vaccines in Development
- Provenge
- DCVax-Prostate
- GVAX
- ProstAtak
- TroVAX
- Telomerase Cancer Vaccine
- MVA-BN Prostate
- HyperAcute Prostate
- MKC1106-PP
- Market Summary
- Potential Competitors and Analysis, 2012
- CHAPTER NINE: BREAST CANCER VACCINES
-
- Overview
- Description of Vaccines in Development
- INGN 225
- CEA VRP Vaccine
- MVA-BN HER2
- Lapuleucel-T
- PX 104.1
- CDX-1307-02
- Tumor Associated Antigen Therapeutic Vaccine - CEA DNA Cancer Vaccine
- MKC1106-PP
- Market Summary
- CHAPTER TEN: GASTROINTESTINAL CANCER VACCINES
-
- Overview
- Description of Vaccines in Development
- GV 1001
- GI-4000
- Avicine
- GVAX
- HyperAcute Pancreas
- Oncophage
- CDX-1307-01
- CRS-100
- CRS-207
- DC Vax
- MKC1106-PP
- Market Summary
- CHAPTER ELEVEN: RENAL CANCER VACCINES
-
- Overview
- Description of Vaccines on the Market
- Oncophage
- Description of Vaccines in Development
- Oncophage
- Reniale
- TroVAX
- IMA901
- AGS-003
- MDX-1106
- MKC1106-PP
- Market Summary
- Potential Competitors and Analysis, 2012
- CHAPTER TWELVE: BRAIN CANCER VACCINES
-
- Overview
- Glioblastoma
- Neuroblastoma
- Description of Vaccines in Development
- DCVax-Brain
- CDX-110
- GliAtak
- Oncophage
- Market Summary
- CHAPTER THIRTEEN: BLADDER CANCER VACCINES
-
- Overview
- Description of Vaccines on the Market
- BCG Therapy (OncoTICE- Organon Teknika) (Immucyst-Sanofi Pasteur)(Pacis-Shire Pharmaceuticals)
- Description of Vaccines in Development
- Bexidem
- CG0070
- MDX-1307-01
- Market Summary
- CHAPTER FOURTEEN: OVARIAN CANCER VACCINES
-
- Overview
- Description of Vaccines in Development
- OVax Autologous Cell Vaccine
- Lapuleucel-T
- Tumor Associated Antigen Therapeutic Vaccine - CEA DNA Cancer Vaccine
- MKC1106-PP
- Market Summary
- CHAPTER FIFTEEN: LEUKEMIA VACCINES
-
- Overview
- Description of Vaccines in Development
- GVAX
- PR1 Peptide Vaccine
- AGS-005
- Market Summary
- CHAPTER SIXTEEN: ISSUES AND TRENDS AFFECTING THE CANCER VACCINE MARKET
-
- Introduction
- Early Detection and Screening
- Monoclonal Antibodies and Therapeutic Vaccines
- Political and Social Pressure
- Insurance and Reimbursement Issues
- Personalized Medicine
- Pharmacogenomics
- Vaccine Strategies
- New Genetic Technique
- Future Growth in Vaccines
- CHAPTER SEVENTEEN: THE CANCER VACCINE MARKET: MARKET
FORECASTS
-
- Overview
- Total Market Size and Forecast
- Market and Competitor Analysis
- CHAPTER EIGHTEEN: CANCER VACCINE CORPORATE PROFILES
-
- Introduction
- Antigenics, Inc
- Avax Technologies, Inc
- Biovest International, Inc
- Cell Genesys, Inc
- Dendreon Corporation
- Genitope Corporation
- GlaxoSmithKline plc
- Merck & Company, Inc
- Northwest Biotherapeutics, Inc
- NovaRx
- Oncothyreon
- Vaccinogen
- Vical, Inc
- CHAPTER NINETEEN: COMPANY NAMES AND ADDRESSES
- TABLE OF EXHIBITS
- CHAPTER ONE: EXECUTIVE SUMMARY
-
- Table 1-1: Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets, 2008-2012
- Figure 1-1: Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets, 2008-2012
- CHAPTER TWO: INTRODUCTION
-
- Table 2-1: Estimated and Projected World Cancer Incidence by Selected Types of Cancer, 2007 and 2020
- Figure 2-1: Estimated and Projected World Cancer Incidence by Selected Types of Cancer, 2007 and 2020
- Table 2-2: Total Cancer Incidence by Sex and Country, 2007 Estimates
- Figure 2-2: Total Cancer Incidence by Sex and Country
- Table 2-3: World Population by Selected Geographical Region, 2007-2050
- Figure 2-4: World Population by Selected Geographical Region, 2007-2050
- Table 2-4: Estimated World Population by Age and Geographical Region, 2007
- Figure 2-4: Estimated World Population by Age and Geographical Region, 2007
- Table 2-5: Percent Population Over 65 by Year and Region
- Figure 2-5: Estimated World Population by Age, 2007 and 2050
- Table 2-6: Life Expectancy at Birth by Selected Countries, 2006
- Table 2-6: United States Average Years of Life Lost Per Person Dying of Cancer, All Races, Both Sexes, 2004
- Table 2-7: United States Estimated Person-Years of Life Lost Due to Cancer, All Races, Both Sexes, 2004
- CHAPTER THREE: CERVICAL CANCER VACCINES
-
- Table 3-1: Estimated World Incidence of Cervical Cancer by Country, 2007
- Figure 3-1: Estimated World Incidence of Cervical Cancer by Country, 2007
- Table 3-2: Cervical Cancer Vaccines Approved and in the Pipeline
- Table 3-3: The Developing Cervical Cancer Vaccine Market, 2008-2012
- Figure 3-2: The Developing Cervical Cancer Vaccine Market, 2008-2012
- Table 3-4: The Developing Cervical Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
- Figure 3-3: The Developing Cervical Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
- Figure 3-4: Anticipated Product Sales by Year for Cervical Cancer Vaccines, 2008-2012
- CHAPTER FOUR: COLON/RECTAL CANCER VACCINES
-
- Table 4-1: Estimated World Incidence of Colon/Rectal Cancer by Country, 2007
- Figure 4-1: Estimated World Incidence of Colon/Rectal Cancer by Country, 2007
- Table 4-2: Colon/Rectal Cancer Vaccines in the Pipeline
- Table 4-3: The Emerging Colon/Rectal Cancer Vaccine Market, 2008-2012
- Figure 4-2: The Emerging Colon/Rectal Cancer Vaccine Market, 2008-2012
- Figure 4-3: Anticipated Product Sales by Year for Emerging Colon/Rectal Cancer Vaccines, 2008-2012
- CHAPTER FIVE: LUNG CANCER VACCINES
-
- Table 5-1: Types of Primary Lung Cancer
- Table 5-2: Estimated World Incidence of Lung Cancer by Country, 2007
- Figure 5-1: Estimated World Incidence of Lung Cancer by Country, 2007
- Table 5-3: Lung Cancer Vaccines in the Pipeline
- CHAPTER SIX: LYMPHOMA VACCINES
-
- Table 6-1: Classification of Non-Hodgkin’s Lymphomas
- Table 6-2: Estimated World Incidence of Lymphoma by Country, 2007
- Figure 6-1: Estimated World Incidence of Lymphoma by Country, 2007
- Table 6-3: Lymphoma Vaccines in the Pipeline
- Table 6-4: The Emerging Lymphoma Vaccine Market, 2008-2012
- Figure 6-2: The Emerging Lymphoma Vaccine Market, 2008-2012
- Table 6-5: The Emerging Lymphoma Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
- Figure 6-3: The Emerging Lymphoma Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
- Figure 6-4: Anticipated Product Sales by Year for Emerging Lymphoma Vaccines, 2010-2012
- CHAPTER SEVEN: MELANOMA VACCINES
-
- Table 7-1: Malignant Condidtions of the Skin
- Table 7-2: Estimated World Incidence of Melanoma by Country, 2007
- Figure 7-1: Estimated World Incidence of Melanoma by Country, 2007
- Table 7-3: Melanoma Vaccines in the Pipeline
- Table 7-4: The Developing Melanoma Vaccine Market, 2008-2012
- Figure 7-2: The Developing Melanoma Vaccine Market, 2008-2012
- Table 7-5: The Developing Melanoma Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
- Figure 7-3: The Developing Melanoma Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
- Figure 7-4:Anticipated Product Sales by Year for Developing Melanoma Vaccines, 2010-2012
- CHAPTER EIGHT: PROSTATE CANCER VACCINES
-
- Table 8-1: Estimated World Incidence of Prostate Cancer by Country, 2007
- Figure 8-1: Estimated World Incidence of Prostate Cancer by Country, 2007
- Table 8-2: Prostate Cancer Vaccines in the Pipeline
- Table 8-3: The Emerging Prostate Cancer Vaccine Market, 2008-2012
- Figure 8-2: The Emerging Prostate Cancer Vaccine Market, 2008-2012
- Table 8-4: The Emerging Prostate Cancer Vaccine Market, Leading Suppliers
Shares by Market Revenues, Projected 2012
- Figure 8-3: The Emerging Prostate Cancer Vaccine Market, Leading
Suppliers Shares by Market Revenues, Projected 2012
- Figure 8-4: Anticipated Product Sales by Year for Emerging Prostate Vaccines, 2010-2012
- CHAPTER NINE: BREAST CANCER VACCINES
-
- Table 9-1: Estimated World Incidence of Breast Cancer by Country, 2007
- Figure 9-1: Estimated World Incidence of Breast Cancer by Country, 2007
- Table 9-2: Breast Cancer Vaccines in the Pipeline
- CHAPTER TEN: GASTROINTESTINAL CANCER VACCINES
-
- Table 10-1: Estimated World Incidence of Gastrointestinal Cancer by Country, 2007
- Figure 10-1: Estimated World Incidence of Gastrointestinal Cancer by Country, 2007
- Table 10-2: Gastrointestinal Cancer Vaccines in the Pipeline
- CHAPTER ELEVEN: RENAL CANCER VACCINES
-
- Table 11-1: Estimated World Incidence of Renal Cancer by Country, 2007
- Figure 11-1: Estimated World Incidence of Renal Cancer by Country, 2007
- Table 11-2: Renal Cancer Vaccines in the Pipeline
- Table 11-3: The Developing Renal Cancer Vaccine Market, 2008-2012
- Figure 11-2: The Developing Renal Cancer Vaccine Market, 2008-2012
- Table 11-4: The Developing Renal Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
- Figure 11-3: The Developing Renal Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
- Figure 11-4: Anticipated Product Sales by Year for Renal Cancer Vaccines, 2008-2012
- CHAPTER TWELVE: BRAIN CANCER VACCINES
-
- Table 12-1: Estimated World Incidence of Brain Cancer by Country, 2007
- Figure 12-1: Estimated World Incidence of Brain Cancer by Country, 2007
- Table 12-2: Brain Cancer Vaccines in the Pipeline
- CHAPTER THIRTEEN: BLADDER CANCER VACCINES
-
- Table 13-1: Estimated World Incidence of Bladder Cancer by Country, 2007
- Figure 13-1: Estimated World Incidence of Bladder Cancer by Country, 2007
- Table 13-2: Bladder Cancer Vaccines in the Pipeline
- CHAPTER FOURTEEN: OVARIAN CANCER VACCINES
-
- Table 14-1: Estimated World Incidence of Ovarian Cancer by Country, 2007
- Figure 14-1: Estimated World Incidence of Ovarian Cancer by Country, 2007
- Table 14-2: Ovarian Cancer Vaccines in the Pipeline
- CHAPTER FIFETEEN: LEUKEMIA VACCINES
-
- Table 15-1: TYPES OF LEUKEMIA
- Table 15-2: Estimated World Incidence of Leukemia by Country, 2007
- Figure 15-1: Estimated World Incidence of Leukemia Cancer by Country, 2007
- Table 15-3: Leukemia Vaccines in the Pipeline
- CHAPTER SIXTEEN: ISSUES AND TRENDS AFFECTING THE CANCER VACCINE MARKET
-
- Table 16-1: Cancer Detection Tests
- CHAPTER SEVENTEEN: THE CANCER VACCINE MARKET: MARKET
FORECASTS
-
- Table 17-1: Cancer Vaccines: Developing and Emerging Cancer VaccineMarkets, 2008-2012
- Figure 17-1: Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets, 2008-2012
- Figure 17-2: Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets by Percent and Vaccine Indication, 2012
- CANCER VACCINE CORPORATE PROFILES
- COMPANY NAMES AND ADDRESSES
-
|
800.298.5603
Int'l: +1.240.747.3096
Questions?
Contact a research specialist >
Most Popular Research
Outsourcing in Drug Discovery: The Contract Research (CRO) Market, 3rd Edition
Clinical Nutrition Products: World Markets, 3rd Edition
World Veterinary Health Products (Animal Pharmaceuticals, Vaccines, OTC and Performance Enhancers)
Vaccines: World Market Analysis, Key Players, and Critical Trends in a Fast-Changing Industry
Vaccines 2009: World Market Analysis, Key Players, and Critical Trends in a Fast-Changing Industry
Lab Automation Markets Worldwide (Next-Generation Systems, Key Companies, Forecasts and Trends)
|
Email a colleague
Printer format
Order by fax